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Abstract 
Mangiferin (Mgf), largely expressed out from the leaves and stem bark of Mango, is a 
potent antioxidant. However, its in vivo activity gets tremendously reduced owing to 
poor aqueous solubility and inconsistent gastrointestinal absorption, high hepatic 
first-pass metabolism and high P-gp efflux. The current research work, therefore, was 
undertaken to overcome the biopharmaceutical hiccups by developing the Mgf-
phospholipid complex (PLCs) loaded in nanostructured lipidic carriers (NLCs). The 
PLCs and NLCs were prepared using refluxing, solvent evaporation and hot 
emulsification technique, respectively with various molar ratios of Mgf and 
Phospholipon 90 G, i.e., 1:1; 1:2; and 1:3. The complex was evaluated for various 
physicochemical parameters like drug content (96.57%), aqueous solubility (25-fold 
improved) and oil-water partition coefficient (10-fold enhanced). Diverse studies on 
the prepared complex using FTIR, DSC, PXRD and SEM studies ratified the formation 
of PLCs at 1:1 ratio. The PLCs were further incorporated onto NLCs, which were 
systematically optimized employing a face centered cubic design (FCCD), while 
evaluating for particle size, zeta potential, encapsulation efficiency and in vitro drug 
release as the CQAs. Caco-2 cell line indicated insignificant cytotoxicity, and P-gp 
efflux, bi-directional permeability model and in situ perfusion studies specified 
enhanced intestinal permeation parameters. In vivo pharmacokinetic studies revealed 
notable increase in the values of Cmax (4.7-fold) and AUC (2.1-fold), respectively, from 
PLCs-loaded NLCs vis-à-vis Mgf solution. In a nutshell, the promising results 
observed from the present research work signified boosted biopharmaceutical 
potential of the optimized PLCs-loaded NLCs for potentially augmenting the 
therapeutic efficacy of Mgf. 
Keywords: QbD, antioxidants, phytomolecule, molecular docking, P-gp efflux, Caco-
2 bidirectional permeability assay, SPIP 
1. Introduction 
Of late, mangiferin (Mgf), a polyphenolic C-glycoside has been gaining enormous 
recognition in pharmaceutical and food industries for its nutritional and 
therapeutic values. It possesses several pharmacological activities like antioxidant 
(Rodriguez et al., 2006), anti-inflammatory (Saha et al., 2016), anti-viral (Zheng and 
Lu, 1990), analgesic (Dar et al., 2005), immunomodulatory (Leiro et al., 2004; Sarkar 
et al., 2004), antidiabetic (Ojewole, 2005), besides other’s. Amongst all these, the 
ability of Mgf to act as a potent antioxidant by scavenging free radicals is known 
to be of immense importance for preventing the potential DNA damage (Zhang, 
2013) and for inhibiting the growth of cancer cells by inducing cellular apoptosis 
(Minglin et al., 2016; Takeda et al., 2016). 
Despite being a potent phytomolecule, the use of Mgf is restricted due to its low 
and variable oral bioavailability (about 1.5 to 5.0%), usually ascribed to its poor 
aqueous solubility (0.1 to 0.3 mg/mL), low lipophilicity, high P-gp efflux, 
considerable first-pass metabolism and cytochrome P-450 mediated metabolism in 
gut enterocytes (Basheer and Kerem, 2015; Khurana et al., 2016). Besides, Mgf 
display rapid clearance from the body via glucuronidation of the hydroxyl groups 
present at position-6 and 7 of its xanthone moiety, which, in turn, tends to reduce 
its potential antioxidant and anticancer activities, due to shorter half-life (van der 
Merwe et al., 2011). 
Mgf, till date, is marketed in the form of conventional tablets, along with other 
antioxidants. However, such formulations exhibit limited fruition for potentiating the 
desired therapeutic efficacy of Mgf owing to the aforementioned biopharmaceutical 
hiccups. A score of formulation strategies including solid dispersions (Qin et al., 2014), 
cyclodextrin inclusion complex (da Rocha Ferreira et al., 2013; Yang et al., 2013), crystal 
engineering and salt formation (Teng and Wu, 2012), phospholipid complex (Ma et al., 
2014) and spray-dried encapsulation (Souza et al., 2013) have already been reported in 
literature. These systems, however, have yielded limited improvement in the 
biopharmaceutical attributes of Mgf, plausibly owing to mere improvement in 
solubility and dissolution behavior. Keeping in view of the potential limitations of the 
existing formulation techniques, the development of newer and more effective 
formulation strategies for Mgf is highly called for.   
The phospholipid systems, in this context, have lately been explored for enhancing 
the biopharmaceutical performance and therapeutic efficacy of bioactives with poor 
hydrophilicity and lipophilicity (Renukuntla et al., 2013). As phospholipids constitute 
a major part of the bio-membrane, these hold good biocompatibility and act as a 
carrier for delivering drugs across the biological barriers (Renukuntla et al., 2013). The 
amphiphilic nature of phospholipids tends to provide enhanced solubility and 
permeability of the drugs, thus improving their oral biopharmaceutical performance 
(Pichot et al., 2013). Other stellar merits of phospholipidic formulations include ease 
of preparation, along with high drug loading capacity and long-term stability. Several, 
literature reports suggest that incorporation of drug-phospholipid complexes into the 
nanostructured systems can further have remarkable increase in the 
biopharmaceutical performance of the drugs (Singh et al., 2012; Rawat et al., 2013; Xia 
et al., 2013).  
The nanosystems composed of lipids not only enable the increased solubility and 
bioavailability of less soluble drugs, but also augment release and permeability of 
drugs, along with gastric protection against degradation from luminal enzymes 
(Renukuntla et al., 2013). Indeed, nanocarriers such as lipid micelles (Neuberg et al., 
2015), solid lipid nanoparticles (Mukherjee et al., 2009; Bunjes, 2010), nanostructured 
lipidic carriers (NLCs) (Khan et al., 2015) and lipid nanocapsules (Sánchez-Moreno et 
al., 2012) have already been reported to hold immense promise for oral delivery of 
poorly water-soluble bioactives. Amongst these nanocarriers, the NLCs are 
considered to be of wider interest owing to their high drug-loading efficiency and 
drug stability (Naseri et al., 2015; Shah et al., 2016). Accordingly, the current work on 
the proposed novel technology was undertaken, wherein the PLCs of Mgf were 
incorporated into NLCs, for further enhancing the biopharmaceutical attributes. The 
nature of the intended research work on Mgf has not been reported in literature so far. 
The present research work, therefore, involves the investigation of dual formulation 
strategies involving the use of PLCs-loaded NLCs for improving the oral 
bioavailability of Mgf. In this regard, PLCs were prepared and extensively 
characterized through FTIR, DSC, PXRD, SEM, and molecular docking studies for 
confirming the formation of complex. Further, intestinal absorption and permeability 
studies on the developed formulations have been performed on Caco-2 bidirectional 
assay model. Subsequently, intestinal perfusion studies and pharmacokinetic studies 
were also performed on Sprague-Dawley (SD) rats for evaluating the improvement in 
permeability, bioavailability and absorption parameters. 
2. Materials and Methods 
Mgf was provided ex-gratis by International Association on Mangiferin Research 
(IAMR), Nanning, Guangxi, China. Phospholipon 90 G (PL) (soybean lecithin at 90% 
of phosphatidylcholine) was provided as gift sample by M/s Phospholipon GmbH, 
Germany. Labrafil M 2125 and Compritol 888 ATO were gifted by M/s Gattefosse, 
Cedex, France. All the solvents were procured from Merk Pvt. Ltd., India.  
2.1 Defining the quality target product profile (QTPP) 
As per the Quality by Design (QbD)-based approach of product development, QTPP 
was set-up not only for the development of NLCs of Mgf’s PLCs but for improving 
the therapeutic performance for the patients benefit. The QTPP described for 
formulating NLCs of Mgf, include key quality characteristics like, dosage form type, 
nature, strength, route of administration, pharmacokinetic and stability requirements. 
2.2 Determining critical quality attributes (CQAs) 
Patient-centric CQAs include both physical and formulation attributes representing 
the out-standing features of NLCs as the target drug product. Among the several 
quality attributes, the prominent attributes critically influencing the product 
performance were selected for the purpose. The selected CQAs include particle size 
(i.e., essential for faster drug absorption), zeta potential (i.e., indicative of the stability 
of drug product), entrapment efficiency (i.e., indicative of the drug loading potential) 
and in vitro percent drug release (i.e., indicative of better absorption from 
gastrointestinal milieu). 
2.3 Molecular modelling and simulation studies  
During complexation process, the role of the molecular modelling and simulation 
studies is to analyse and confirm the potential interactions between Mgf and PL. Chem 
Draw Ultra 12.0 software was utilized to draw the chemical structure of Mgf. Further, 
ChemBio 3D Pro-12.0 software (M/s Cambridgesoft, Cambridge, USA) was employed 
to generate the 3D model by minimizing the free energy. Docking studies were 
conducted between Mgf and analogue of phospholipid in the human body, i.e., 
phosphatidylcholine transfer protein using MGL tool (Autodock software version 
1.5.6) (M/s GNU General Public Licence, CA, USA). For this, protein data bank, i.e., 
PDB 1LN1 was employed. A grid box of center x, y, z = 46.358 Ǻ, 48.638 Ǻ and 19.7 Ǻ 
was created around Mgf to wrap it completely (Lee et al., 2013). 
2.4 Preparation of the Mangiferin’s Phospholipid Complex (PLCS) 
Solvent-evaporation method was used for the preparation of PLCs as per the reported 
procedure (Ma et al., 2014). Briefly, the required amount of Mgf and PL in the 
stoichiometric ratio 1:1, 1:2 and 1:3 was dissolved in 100 mL of 80% ethanol by 
magnetic stirring at room temperature. The mixture was refluxed at 60°C temperature 
for 2 h. The ethanol was evaporated at reduced pressure using rotary flask evaporator 
at 40 °C. The resultant complex was collected and stored under dried condition in 
desiccators. 
2.5 Characterization of the prepared PLCs 
2.5.1 Drug content determination 
The content of Mgf in the PLCs was determined by HPTLC method previously 
reported by us (Khurana et al., 2016). Accurately amount of pure Mgf and PLCs (10 
mg each), were solubilised in methanol, and diluted simultaneously in the mobile 
phase before its application on the silica gel plate. Subsequently, densitometric 
scanning of Mgf was performed at λmax of 262 nm at Camag TLC Scanner for 
quantifying the drug content through already reported and validated method by us 
(Khurana et al., 2016). 
2.5.2 Solubility studies and partition coefficient 
Excess of Mgf, physical mixture of Mgf and PL, and PLCs were dissolved in 5 mL of 
water and n-octanol. Each experiment was conducted in triplicate with continuous 
shaking in a shaker for 48 h. Further, centrifugation was performed at 10,000 rpm 
(5,590 × g) for a period of 10 min. HPTLC was employed to analyse the supernatant 
obtained after filtration (0.22 µm) after apt dilutions. 
2.5.3 Powder X-Ray diffraction (PXRD) 
The PXRD studies were carried out on Mgf, PL, physical mixture and PLCs, where the 
diffraction patterns were recorded under ambient conditions on X-ray powder 
diffractometer (D8 Advance, Bruker, Karlsruhe, Germany) using Cu Ka radiation 
(=1.54 A˚) at 40 kV, 40 mA passed through nickel filter (Yang et al., 2013). 
 
 
2.5.4 Differential scanning calorimetry analysis (DSC) 
The DSC studies were carried out on 1-2 mg sample of Mgf, PL, their physical mixture, 
PLCs and PLCs-NLCs by DSC Q20 (M/s TA Instruments, Detroit, USA) in crimped 
aluminium pans, heated from 25 to 250 °C at a scanning rate of 10 °C/min (Ma et al., 
2014). 
2.5.5 Fourier-transform infrared (FTIR) spectroscopy  
FTIR spectra of Mgf, PL, their physical mixture, PLCs and PLCs-NLCs were obtained 
using an FTIR-8300 spectrophotometer (Shimadzu, Japan) as per the procedure 
reported by Beg and associates (Beg et al., 2016). 
2.5.6 Scanning electron microscopy (SEM) 
In order to have better conceptualization and visualization, SEM (JEM-2100F (M/s 
Jeol, Tokyo, Japan) studies were performed on Mgf, PL, physical mixture and PLCs 
with instrument named. Mgf, PL, physical mixture and PLCs were coated with gold 
in a sputter coater and their surface morphology was viewed and photographed (Beg 
et al., 2016). 
2.6 Development of Nanostructured Lipidic Carriers (NLCs) 
2.6.1 Risk assessment studies 
To identify the possible critical material attributes (CMAs) and/or critical process 
parameters (CPPs) affecting the critical quality attributes (CQAs), risk assessment 
studies were carried out by constructing Ishikawa fish-bone diagram, to delineate the 
potential cause-and-effect relationship among the product and process variables. Out 
of this diagram, key material attributes (MAs)/process parameters (PPs) were 
prioritized. Further, for qualitative analysis of low, medium and high-risk(s) related 
with each MAs and PPs, the risk estimation matrix (REM) was built. 
2.6.2 Screening of the lipids 
Various solid and liquid lipids were screened on the basis of their suitability for Mgf. 
Fixed quantity of the lipids were taken in the culture flasks and excess amount of Mgf 
was added to them. The solid lipids were allowed to melt at 80 °C for 2 h using a 
thermostatically controlled water bath (M/s Rivera, Mumbai, India). On the other 
hand, the solubility studies for the liquid lipids were carried out at ambient 
temperature. After 48 h, an aliquot (100 µL) of the lipids was taken from the 
supernatant after centrifugation at 5,000 rpm (1,190 × g), suitably diluted in 7:3 ratio 
mixtures of methanol and chloroform to solubilise Mgf, and filtered for analysis using 
previously validated and reported HPTLC method at a λmax of 262 nm (Khurana et al., 
2016). 
2.6.3 Preparation of the PLCs-NLCs 
The NLCs were prepared by hot emulsification and ultrasonication method. The oil 
phase, containing a mixture of solid and liquid lipids in the ratio of 90:10 and 70:30, 
was heated up to 80°C, followed by addition of PLCs, and subsequently complete 
solubilization in the molten lipid phase. Simultaneously, the aqueous phase 
containing Tween 80 as surfactant and soy lecithin (50 mg) as stabilizer were mixed in 
10 mL of water and heated up to the identical temperature (Zhao et al., 2013). The ratio 
of lipid to aqueous phase was kept between 1:10. Using a Ultra-Turrax homogenizer 
fixed at 10,000 rpm (5,590 × g), the aqueous phase was mixed with the lipid phase for 
30 min. The formed emulsion was further ultra-sonicated using a probe sonicator. This 
ultra fine dispersion containing NLCs was cooled down in an ice bath and stored until 
use. 
2.6.4 Systematic development of the NLCs employing FCCD 
The most influential factors identified from REM were employed for systematic 
optimization using face centered cubic design (FCCD). A total of thirteen formulations 
were prepared as per the FCCD employing two factors, viz. solid lipid concentration 
(X1) and surfactant concentration (X2) at three levels of each, including low (-1), 
medium (0) and high (+1) levels with quintuplicate studies conducted for the center 
point (0, 0) formulation. The CQAs selected for the prepared formulations include, 
particle size, zeta potential, encapsulation efficiency and drug release.  
2.7 Characterization of the prepared PLCs-NLCs 
2.7.1 Particle size and zeta potential 
For particle size, polydispersity index (PDI) and zeta potential measurement, the 
NLCs prepared as per the experimental design were diluted 100-fold with distilled 
water employing Zetasizer ZS 90 instrument (M/s Malvern Instruments, 
Worcestershire, UK) based on dynamic light scattering technique. 
2.7.2 Entrapment efficiency 
As per the generated design matrix, entrapment efficiency of the NLCs-loaded with 
PLCs was determined by centrifuging the dispersion at 10,000 rpm (5,590 × g). The 
obtained pellet was made to digest by Triton-X-100 (0.1% w/v), followed by 
ultrasonication for 15 min to completely remove the drug from nanostructured 
systems (Zhao et al., 2013). Mgf was extracted in methanol and filtered (0.45 μm) to 
obtain a fine dispersion. The amount of drug entrapped was quantified employing a 
previously developed, validated and reported HPTLC method (Khurana et al., 2016). 
Eq. 1 was employed to calculate the entrapment efficiency, as follows: 
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where, D1; amount of drug added and D2; unentrapped drug 
2.7.3 In vitro drug release studies 
Dialysis bag method was employed to study in vitro drug release behaviour from 
PLCs-NLCs, in 250 mL of 0.1 N HCl (pH 1.2) for first 2 h, followed by phosphate buffer 
(pH 6.8) up to 24 h at 37±0.5 °C; 100 rpm. The PLCs-NLCs, equivalent to 10 mg was 
placed in the dialysis bag, and 5 mL of sample was withdrawn at defined time 
intervals. In order to maintain the sink conditions, replenishment with an equal 
volume of fresh dissolution media was done. 
2.7.4 Transmission electron microscopy (TEM)  
An aliquot of 1 mL of the optimized PLCs-NLCs formulations were diluted in 250 mL 0.1N 
HCl and used for TEM analysis. A drop of the sample was placed on copper grids, stained 
with 1% phosphotungstic acid solution for 30s, and visualized under electron microscope 
(JEM-2100 F, M/s Jeol, Tokyo, Japan) (Beg et al., 2015). 
2.7.5 Mathematical modelling and optimization data analysis 
Multiple linear regression analysis (MLRA) with second-order quadratic polynomial 
models was employed to carry out DoE-based optimization data analysis. Moreover, 
suitability of the selected mathematical model was analyzed using various diagnostic 
plots. To understand the relationship amongst various CQAs, CMAs and CPPs, 
response surface analysis was conducted employing 3D-reposne surface plots (Singh 
et al., 2016). 
2.7.6 Search for the optimum formulation and validation studies 
Initially, a feasible region was located by assigning the desirable values for each of the 
CQAs, followed by narrowing down the constraints to predict the optimum solutions. 
Numerical optimization also helps in choosing the best solution with desirability 
closer to one. Further, design space within the overlay plot also demarcates the 
optimized formulation (Singh et al., 2005). 
2.8 Caco-2 cell line studies 
2.8.1 Caco-2 cell culture 
Caco-2 cell line, Caucasian colon adenocarcinoma (cell passages between 40 to 55), 
was procured from European Collection of Authenticated Cell Cultures (ECACC), 
Public Health England, Salisbury, England. Cells were grown in EMEM media 
containing 2 mM glutamine, 1% (v/v) non-essential amino acid solution (NEAA), 10% 
(v/v) foetal bovine serum (FBS), at 37 °C in an atmosphere of 5% CO2 (ESCO, UK) in 
the tissue culture flasks (75 cm2; Thermo, USA). Once cells were 90% confluent, 0.1% 
trypsin-EDTA solution was employed. 
2.8.2 Cell viability assay 
For cell viability studies, 1 × 103 cells/cm2 were seeded on 96 well plates (M/s Thermo 
Fischer Scientific, Roskilde, Denmark), and the cytotoxicity was evaluated by 
PrestoBlueTM cell viability reagent (Invitrogen, MD, USA). The medium was removed 
before the start of each experiment, and 90 μL of 1000 µmol concentration of Mgf, 
physical mixture, PLCs and PLCs-NLCs diluted with media were added to their 
respective wells. A volume of 10 μL of PrestoBlue  was added to each well after 24, 48 
and 72 h of treatment, and the fluorescence was measured, after 1 h of incubation 
using a microtiter plate reader at excitation/emission 535/612 nm (Tecan, Genios Pro, 
Austria). 
2.8.3 Bidirectional permeability assay 
The cellular permeability of Mgf, physical mixture, PLCs and PLCs-NLCs was studied 
in the apical to basolateral (A→B) and basolateral to apical (B→A) directions in Caco-
2 cells. To determine permeability on fully grown monolayer, cells 
(2 × 104 cells/cm2) were seeded on polyester sterile membrane, polystyrene plates and 
grown for 19-21 days (12 mm diameter inserts, 0.4 μm pore size) (Corning 
Incorporated, Costar®, NY, USA). The media was changed every alternate day such 
that there is no depletion of nutrients to the cells. Besides, transepithelial electrical 
resistance (TEER; Millicell®-ERS-2 Voltohm meter, M/s Millipore Corporation, 
Billerica, MA, USA) value was measured in order to monitor the uniform growth of 
the Caco-2 monolayer. TEER value is also an indicative of the extent of opening of 
cellular tight junctions (Chaurasiya et al., 2012; Sermkaew et al., 2013; Neves et al., 
2015). The experiment was started on 21st day, when the monolayers reached a 
constant TEER value, i.e., at about 1700 ohm and equilibrated with pre-warmed HBSS. 
Further, on apical side 0.5 mL pre-warmed HBSS containing Mgf, physical mixture, 
PLCs and PLCs-NLCs, while 1.5 mL of blank HBSS was added to the basolateral side. 
On the similar heels, the same formulations were also added on B side and blank HBSS 
was added to the A side of the cells to better evaluate the permeability assay. Post 
incubation, 0.2 mL of medium at the B side was withdrawn at a periodic time intervals 
of 0.5 h, 1 h, 2 h and 3 h, and replaced with fresh medium to investigate A→B 
transport. Similarly, from the apical side, 0.2 mL of medium was withdrawn and 
replaced with fresh medium for investigating B→A transport. Drug concentration on 
both the sides was determined using HPTLC analytical method (Khurana et al., 2016). 
From the linear slope of the plot between drug permeated and time, apparent 
permeability coefficient (Papp; cm/s) was determined: 
                        
AC
tQ
Papp




/
                                                             ……….. Eq 2 
where, ΔQ/Δt is the steady state flux; C0 is the initial drug concentration on apical or 
basolateral side; and A is the surface area of the membrane (cm2). 
2.8.4 Qualitative and quantitative cellular uptake 
Qualitative cellular uptake investigations were conducted by fluorescence microscopy 
on Caco-2 cells employing rhodamine-123 (Rh-123) as the tracker dye, loaded onto 
blank NLCs (Chaurasiya et al., 2012). Cells (1 ×105 per well) were plated on glass 
coverslips in EMEM media and allowed to adhere overnight. Once adhered, the cells 
were treated with 0.078 µM Rh-123 loaded NLCs for 1 h and 3h at 37 °C. Subsequently, 
the cells were washed thrice with pre-warmed PBS and imaged live under PBS on a 
modified Zeiss Cell Observer imaging system using a Zeiss EC Plan-Neofluar 40x/1.3 
oil objective. On the other hand, simultaneously another set of cells grown of cover 
slips were treated in a similar manner. However, these sets of cells were fixed with 
paraformaldehyde and washed thrice with PBS prior to their mounting on 
Vectashield® mounting medium with DAPI and were observed on the same 
instrument. Rh-123 and DAPI were imaged using a GFP/DAPI filter set at 
excitation/emission wavelength of 450-490nm/500-550nm and 335-383nm/420-
470nm, respectively. Analysis of the images was carried out using Zeiss ZEN desk 
imaging software. For quantitative measurement, cells (1x105) were seeded in each 
well of the 6-well plate and incubated for overnight. Rh-123 loaded NLCs (100 µg/mL) 
were added to each well and cells were incubated for different time intervals, as 
during qualitative measurement. Medium was removed after incubation for a period 
of 1 h and 3 h, subsequently, the cells were washed, tyrpsinized, and re-suspended in 
cold PBS for immediate flow cytometry analysis. Rh-123 signals were detected in FL-
1 channel of BD FACSAria flow cytometer. A total of 10,000 events were analysed and 
data were analysed on Flowing version 2.5.1 (Pertuu Terho, Turku Centre for 
Biotechnology, University of Turko, Finland). 
2.8.5 P-gp efflux assay 
The overexpression of P-gp efflux proteins in Caco-2 cells has been well documented in 
several literature reports (Faassen et al., 2003; Konsoula and Jung, 2009). In Caco-2 cells, P-gp 
confers resistance by preventing the absorption of drugs and bioactives through the cells, 
thereby inhibiting it to reach systemic circulation (Shugarts and Benet, 2009). For evaluating 
the P-gp efflux, the multi-drug resistance dye efflux assay kit (Chemicon International, USA) 
was employed (International, 2016). The efflux activity was measured to determine the 
intracellular accumulation of two fluorescent dyes viz. Rh-123 and DiOC2, to access the 
inhibitory activity of Mgf, PLC, PLCs-NLCs on MDR1 and BCRP transporters, respectively. 
Caco-2 pellet containing 2.5 × 105 cells was incubated with Rh-123 alone, Rh-123 with 
vinblastine at 37 °C and 4 °C, Rh-123 loaded-PLCs and PLCs-NLCs for 1 h. All the 
formulations were suspended in RPMI-1640 medium (Sigma-Aldrich, UK). Likewise, to 
investigate the potential of Mgf and the developed formulations to block the activity of BCRP 
transporters, DiOC2 dye was employed. Similarly, Caco-2 cells (2.5 × 105) were incubated with 
DiOC2 alone, DiOC2 and vinblastine at 37 °C and 4 °C, DiOC2-loaded Mgf, PLCs and PLC-
NLCs for another 1 h. The cells were washed with pre-warmed PBS and the fluorescence 
intensity was measured in the presence of Rh-123 and DiOC2-loaded formulations, in a Tecan 
fluorescence microplate reader at excitation and emission wavelengths of 485 nm and 530 nm, 
respectively. 
2.9 In situ single pass intestinal perfusion (SPIP) studies 
Unisex wistar rats weighing 250-300 g were fasted for 24 h (Animal approval no. 
578/IAEC). Animals were randomly grouped namely, i.e., Group I with Mgf, Group 
II Mgf with verapamil (a P-gp efflux inhibitor), Group III with PLCs, and Group IV 
with PLCs-NLCs. The study was performed as per the procedure already reported by 
our group (Bandyopadhyay et al., 2012). Briefly, on the anaesthized animal, the inlet 
and outlet was created on the intestine after incising the abdomen and were further 
cannulised to perfuse Kreb’s buffer. After a periodic time interval of 15 min, aliquots 
of 1 mL were withdrawn.  Permeability parameters viz. effective and wall 
permeability, and absorption parameters viz. fraction absorbed and absorption 
number were calculated (Daniel, 1991; Singh et al., 2016). 
2.10 In vivo pharmacokinetic studies 
In vivo pharmacokinetic studies were conducted (Animal approval no. 578/IAEC) 
with single dose parallel design study. Each group contained six animals, Group I 
were administered with free Mgf solution, Group II were administered with PLCs and 
Group III were PLCs-NLCs complex containing Mgf equivalent to 30 mg/Kg by oral 
gavage (Lopesa et al., 2013), respectively. About 100 µL of blood was withdrawn at 0.5, 
1, 2, 3, 6, 12, 18, 24 and 36 h from the retro-orbital plexus. Heparin coated vials 
containing blood were centrifuged at 10,000 rpm (5,590 × g) for 10 min to extract 
plasma which was subjected to HPTLC analysis to estimate Mgf. The validation data 
of the developed method has already been previously reported by our group 
(Khurana et al., 2016). To estimate the pharmacokinetic parameters, data analysis was 
carried out using compartmental and noncompartmental modelling options of 
WinNonlin software, version 5.0 (M/s Thermo Scientific, USA) (Singh et al., 2009). 
3. Results and Discussion 
The PLCs was formed employing stoichiometric ratios of 1:1, 1:2, and 1:3 and the 
following parameters were estimated to screen the best ratio. 
3.1 Systematic optimization of the NLCs  
3.1.1 Defining the QTPP 
For maximal therapeutic efficacy and patient safety, the objectives of the target 
product were defined by summarizing the quality characteristics. Supplementary 
Table 1 enlists the QTPP aimed for formulating the NLCs of Mgf. The basic objective 
underlying the selection of NLCs can be ascribed to their lipidic nanostructured 
nature, which helps in absorption of the drugs through gastrointestinal route. 
Although several literature reports (Patil et al., 2015; Singh et al., 2016; Valicherla et al., 
2016) have documented the use of lipidic systems for BCS Class II and IV bioactives 
like Mgf, yet the current studies endeavoured at developing the PLCs-loaded with 
NLCs systematically for enhance the oral bioavailability. 
3.1.2 Identification of the CQAs 
The CQAs for NLCs were earmarked to meet the desired QTPP objectives which 
include particle size, zeta potential, entrapment efficiency and time required for 80% 
of drug release. Selection criterion of the CQAs was based upon the prior literature, 
knowledge and experience on the NLCs formulations and enlisted in Supplementary 
Table 2 with suitable justifications. 
 
3.2 Molecular docking and simulation:  
Docking studies unearth the formation of intermolecular hydrogen bonding between 
Mgf and phosphatidylcholine transfer protein. As shown in Figure 1, the docking 
patterns indicated two prominent hydrogen bonding, between free hydroxyl groups 
of Mgf and NH of TRP 30 and GLN 12, at a distance of 1.982 Ǻ and 2.142 Ǻ, 
respectively. The complex formation and thermodynamic stable conformation 
between Mgf and protein is primarily due to the meek reduction in the activation 
energy. Final docking energy exhibited was –7.9 kcal/mol, indicative of the free –OH 
groups on Mgf responsible for the complex formation (Beg et al., 2016). 
3.3 Characterization of PLCs 
3.3.1 Physical evaluation and drug Content 
Mgf (10 mg) and Phosholipon 90G were stoichiometrically mixed in 1:1; 1:2 and 1:3 
ratio to prepare the complex. The physical appearance of the complex was found to 
be semi-solid in nature, while evaluation content in all the three ratios (i.e., 1:1; 1:2 and 
1:3) of complexes was found to be of 96.57% ± 1.02% (1:1), 95.64% ± 0.92% (1:2) and 
95.18% ± 1.11%.  
3.3.2 Solubility and oil water partition coefficient 
All the complexes, prepared in different molar ratios, showed 25-folds higher aqueous 
solubility and 10-folds higher oil-water partition coefficient vis-a-vis Mgf alone (Table 
1). It could be well inferred from the studies that varying ratios of Mgf and PL during 
complex formation caused no significant improvement in the values of solubility and 
partition coefficient of the drug. This indicated that 1:1 molar ratio was suitable for 
forming the complex between the Mgf and PL, which was selected for further studies.  
Table 1:  Solubility and oil-water partition coefficient of Mgf, physical mixture 
and PLCs 
 
Samples Solubility in water (mg/mL) Oil-water partition coefficients 
Mgf 1.36  ± 0.25 0.83 ± 0.21 
Physical 
mixture 
3.79  ± 1.98 1.23 ± 0.54 
PLCs (1:1) 34.25 ± 1.98 8.52 ± 0.98 
PLCs (1:2) 33.22 ± 2.75 8.91 ± 1.26 
PLCs (1:3) 34.46 ± 1.10 7.90 ± 1.03 
Mean ± SD (n=3) 
3.3.3 PXRD studies 
The PXRD depicted in Figure 2 (A) for Mgf showed sharp peaks, indicating its highly 
crystalline nature, while a halo pattern was observed for PL indicating its amorphous 
nature (Figure 2 B). Physical mixture of Mgf and PL (Figure 2 C) shows some of the 
prominent diffraction peaks of Mgf. On the contrary, diffraction patterns of PLCs 
(Figure 2 D) show a halo pattern indicating loss of crystallinity of Mgf in the PLCs.  
3.3.4 DSC studies 
The DSC heating curve in Figure 3 (A) for Mgf indicated a sharp endothermic peak at 
277.08 °C, ostensibly owing to the melting point of crystalline Mgf. Figure 3 (B), 
portraying PL, did not exhibit any distinct melting event plausibly due to its non-
crystalline nature, while an endothermic peak at 231.13 °C was observed due to its 
possible degradation pattern. However, the physical mixture of Mgf and PL (Figure 3 
C) exhibited significant reduction in the melting endotherm of Mgf which could be 
due to the miscibility of Mgf and PL. However, PLCs of Mgf shows a prominent 
endothermic event at around 140°C which might be attributed to formation of a 
characteristic ordered structure for the complex. It also showed disappearance of DSC 
events for pure Mgf and phospholipid (Semalty et al., 2012). The results were found to 
be in close consonance with those of the results reported by Ma and associates (Ma et 
al., 2014).  
 
3.3.5 FTIR Studies 
The FTIR studies of Mgf (Figure 4 A) revealed functional groups of peaks at 3368.00 
cm−1 (O-Hstr), 2932.88 cm−1 (aliphatic C-Hstr), 1636.75 cm−1 (C=Ostr), 1497.10 cm−1 (CH–
CHstr) and 1253.42 cm−1 (C-Ostr). Peak at 1086.93 cm−1 showed the presence of C–C 
stretching in the structure of Mgf. The FTIR spectrum of PL (Figure 4 B) showed peaks 
for functional group at 3390.30 cm−1 (O-Hstr,), 2923.39 cm−1 (aliphatic C-Hstr), 1733.16 
cm−1 (C=Ostr, COOH) and 1642.48 cm−1 (C=Ostr). 
The physical mixture, however, showed characteristic functional peaks (Figure 3 C) at 
3369.44 cm−1 (O-Hstr), 2926.75 cm−1 (C-Hstr, aliphatic), 1737.04 cm−1 (C=Ostr, COOH, 
phospholipid) and 1640.85 cm−1 (C=Ostr, Mgf), indicating no interaction existing 
between Mgf and PL. On the other hand, the complex showed shifting and broadening 
of the functional peaks of Mgf (Figure 3 D) from 3390.30 to 3430.87 cm-1 for O-Hstr 
indicating presence of weak H-bonding interaction. These results indicated that 
phenolic hydroxyl group of Mgf might have been responsible for interaction with the 
quaternary amine nitrogen in the PL to form PLCs, while minor shifting in the peaks 
and their intensity were observed in the functional peaks from 1638.55 to 1430.91 cm-
1 (Zhao et al., 2013). The results are in consonance with the values reported in literature  
(Semalty et al., 2012). 
 
3.3.6 Scanning electron microscopy (SEM) 
Figure 5 illustrates the surface morphology of Mgf and its complex. The Figure 5 (A) 
shows longitudinal column shaped crystals of Mgf, while Figure 5 (B) shows 
amorphous nature of PL. No change in surface morphology was observed in the 
physical mixture of Mgf with PL, as depicted in Figure 5 (C). In case of complex 
(Figure 5 D), however, the crystallinity of Mgf disappeared ascribable to its 
complexation with PL.  
As a naturally occurring flavonoid exhibiting poor lipophilicity (log P of -0.36) 
(FooDB., 2016) and hydrophilicity (sparingly solubility in water; 0.16 mg/mL) (Acosta 
et al., 2016) as well as in lipidic solvents, phospholipids can be considered as potential 
carriers to ameliorate these hiccups of Mgf, a BCS Class IV bioactive. Therefore, 
phospholipid complex of Mgf i.e., PLCs were prepared first, then incorporated in the 
nanostructured lipidic carriers (NLCs) for improved scalability, deliverability through 
oral route and handling of drug delivery systems.  
 
3.4 Risk assessment studies 
The causes and sub-causes affecting the CQAs were indentified through Fish-bone 
diagram constructed in Supplementary Figure 1. Subsequently, the “prominent few” 
input variables were identified from the “plausible so many”. These included drug 
particle size, type of phospholipid, type of surfactant, amount of solid lipid and liquid 
lipid, amount of emulgent as MAs and as the reflux temperature and time, 
ultrasonication time and cycles, type of stirring, stirring speed and stirring time, 
homogeniser speed and homogenisation time as process parameters (PPs). The 
selected MAs and PPs were subjected to risk assessment studies using REM by 
assigning them low, medium and high risk levels. These levels were earmarked 
keeping in consideration the patient perspectives following the brainstorming 
sessions among the team members. Supplementary Table 3 illustrates the REM with 
ratio of solid and liquid lipids, and amount of emulgent observed to be the high risk 
parameters influencing the formulation CQAs, i.e., particle size, zeta potential, 
encapsulation efficiency and in vitro drug release. Further, ultrasonication time and 
ultrasonication cycles, stirring speed and stirring time and homogeniser speed and 
homogenization time as the PPs were observed to exhibit medium risk levels. The 
aforesaid MAs and PPs were therefore, considered as critical CMAs and CPPs, and 
were further subjected to systematic formulation optimization studies. However, API 
particle size, and types of phospholipid and surfactant were found to exhibit low risks. 
Thus, phospholipid and surfactant type were fixed with i.e., Phospholipon 90G and 
Tween 80 on the basis of solubility results. 
3.5 Selection of the lipids 
Equilibrium solubility studies as Mgf were performed on various solid and liquid 
lipids. Solubility of drug in solid lipids was found to follow the order of Compritol 
888 > stearic acid > isopropyl myristate > cetyl palmitate > glyceryl monostearate > 
soy lecithin. Mgf showed maximal solubility in Compritol 888 while minimal 
solubility in soy lecithin. Soy lecithin was used in the formulation as an edge activator 
which enables the vesicle to deform without losing their structural integrity (Yusuf et 
al., 2014). Despite low solubility of the drug in it, many scientific reports on NLCs have 
documented the usage of soy lecithin for reducing the particle size and augmenting 
absorption characteristics of drug(s)  (Andalib et al., 2012; Pezeshki et al., 2014). 
Solubility of drug in the liquid lipids and surfactants was found to follow the order, 
Labrafil M 2125 > Capmul MCM > Lauroglycol FCC > Capryol 90 and Tween 80> 
Tween 40> Cremophor RH 40> Cremophor EL. Hence, Labrafil M 2125 and Tween 80 
were chosen as the liquid lipid and surfactant, respectively. Table 2 enlists the design 
matrix indicating thirteen experimental runs obtained for the NLCs, along with the 
factor levels in coded units and actual form. Prepared complex of Mgf was 
incorporated into the nanolipidic carriers through bottom-up approach, where the 
lipophilic complex was solubilized in the lipidic vehicle, used for the preparation of 
nanocarriers (Li et al., 2013; Beg et al., 2016). 
Table 2: Optimization design matrix enlisting the levels employed for CMAs of 
NLCs in FCCD 
Factors Type Levels 
Low (-1) High (+1) 
Solid lipid (X1) Numerical 700 mg 900 mg 
Tween 80 (X2) Numerical             250 mg 450 mg 
Optimization design as per thirteen factors, three level FCCD 
Trials                      Solid lipid  (X1) Tween 80 (X2) 
F1* 0 0 
F2* 0 0 
F3 0 1 
F4* 0 0 
F5 -1 1 
F6 0 -1 
F7* 0 0 
F8 1 1 
F9 -1 -1 
F10 1 0 
F11* 0 0 
F12 1 -1 
F13 -1 0 
 
3.6 Characterization of the prepared NLCs 
3.6.1 Particle size and TEM analysis 
The NLCs showed particle size ranging between 151 and 415 nm, which indicate their 
nanostructured nature, by and large. The results revealed that particle size was found 
to be depending on the combined effect of the solid lipid and concentration of the 
surfactant in the prepared formulations. The smaller particle size was observed for the 
formulations containing lower concentration of lipids and higher concentration of 
emulgents. Figure 6 (A) potrays the particle size and Figure 6 (B) depicts the electron 
microscopy analysis of optimized PLCs-NLCs. 
3.6.2 Zeta potential 
The zeta potential values for NLCs were found to be ranging between -10.41 and  
-42.1 mV, indicating negatively charged nature of the prepared formulations. This can 
be attributed to the PEG-esters and a glycerides fraction of the lipid and nonionic 
nature of the surfactant employed for the preparation of NLCs (Pezeshki et al., 2014). 
The observed high values of zeta potential vouched potentially physical stability of 
the prepared NLCs. 
3.6.3 Encapsulation efficiency 
Encapsulation efficiency was found to be in the range of 68% and 87%. High 
entrapment was observed with increasing lipid and intermediate levels of surfactant, 
attributable to the maximal drug solubilization capacity at this particular combination. 
The results revealed that use of intermediate to high concentration of lipids, and 
intermediate concentration of surfactant produced maximal entrapment efficiency 
values. 
3.6.4 In vitro drug release  
Figure 7 shows in vitro drug release profile of PLCs-loaded NLCs prepared as per 
design matrix and maximal drug release (i.e., >80%) was found to be within 20 h. It 
was further observed that faster drug release was from the formulations containing 
lower concentration of lipid and higher amount of surfactant. However, the 
formulations containing intermediate to lower levels of lipids showed sustained drug 
release profile, plausibly owing to the slower diffusion rate of the drug from the 
tortuosity of the lipid matrix. Interestingly, the results also construed that the effect of 
increase in the levels of liquid lipid was responsible for evaluating drug release rate, 
ostensibly owing to loosening of the packing of drug within the lipid matrix (Dhawan 
et al., 2010). Mgf’s PLCs-loaded NLCs exhibited sustained drug release profile, 
considered to be essential for enhancing the therapeutic response for prolonged 
period of time (Fang et al., 2012; Tran et al., 2014). 
 
3.6.5 DSC and FTIR analysis of PLCs-NLCs  
PLCs-NLCs showed a sharp new endothermic peak at 116.85°C (Figure 3E) suggesting 
the disappearance of DSC events of Mgf, PL and PLCs. FTIR spectra obtained for 
PLCs-NLCs revealed peaks at 3433.51 cm-1 (O-Hstr), 2923.69 cm−1 (C-Hstr, aliphatic) 
and changing of the intensity of all peaks from 1737.67 to 1105.40 cm−1 suggesting that 
PLCs have been incorporated in NLCs. 
3.7 Mathematical modelling and optimization 
MLRA method was employed to fit in the experimental data obtained as per the 
selected design into the second-order quadratic polynomial model. Table 3 enlists the 
coefficients obtained for each of the CQAs as per the model Eq. 1, which revealed the 
presence of interactions among the studied factors on the CQAs. Further, the model 
developed using parameters like higher values of correlation coefficient (R), ranging 
from 0.9874 and 0.9988 and insignificant lack of fit revealed aptness of the selected 
model. 
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where, Y = response variables, β0= intercept, β1 to β3 = coefficients of linear model 
terms; β4 to β6 = coefficients of linear interaction terms, β7 to β8 = coefficients of 
quadratic terms. 
Table 3:        Coefficients of polynomial model equations with various statistical 
parameters for the response variables of NLCs of mangiferin 
Coefficient 
code 
Polynomial coefficients for responses 
Particle  
size 
Zeta  
potential  
Entrapment 
efficiency 
Drug  
release 
β0 216.20 -25.53 79.00 83.60 
β1 -13.50 8.10 1.00 0.50 
β2 -45.00 6.19 -6.50 -1.00 
β3 62.50 7.15 0.75 -4.75 
β4 40.30 -6.87 7.00 4.90 
β5 153.80 1.12 -4.50 2.40 
β6 93.50 -6.09 5.75 -1.25 
β7 74.50 -10.55 -1.75 -0.25 
β8 184.30 7.08 0.25 -2.15 
R 0.9996 0.9345 0.9240 0.9238 
P-value <0.0001 <0.001 <0.001 <0.001 
     
 
3.7.1 Response surface analysis 
The 3D-response surface plots as depicted in Figure 8, revealed the correlation among 
selected factors for better product and process understanding. 
The said plots for particle size (Figure 8 A) revealed curvilinear relationship with an 
initial increasing trend from low to intermediate levels, followed by a declining phase 
at higher levels. On the other hand, the effect of Tween 80 was found to be quite linear 
on particle size. However, lower concentration of lipids and higher concentrations of 
surfactants showed minimum particle size. 
In Figure 8 B, solid lipid shows a declining trend, while surfactant, i.e., Tween 80 
shows positive influence on zeta potential. At lower levels of Tween 80 with increasing 
content of lipid, significant interaction was observed on the values of zeta potential. 
Maximal values for zeta potential were observed at higher concentration of lipids and 
surfactant. 
The response surface plot depicting the influence of entrapment efficiency was found 
to be highly pronounced at all the levels of lipids (Figure 8 C). Moreover, the plot 
shows an initial declining trend followed by an increasing trend for entrapment 
efficiency from low to high levels of lipid, at high levels of surfactant. Maximum 
entrapment efficiency was observed both at either low or high solid lipid levels, 
coupled with preferably higher levels of surfactant. 
The effect of ratio of solid to liquid lipid was found to possess positive influence on 
the values of Q16h (Figure 8 D), while the influence of Tween 80 shows a diminishing 
trend. Minimum percent drug release exhibiting controlled release profile was 
observed at higher lipid concentration and intermediate Tween 80 concentration.     
3.7.2 Search for the optimum formulation and validation studies 
To attain the desired intents of minimum particle size (<90 nm), higher zeta potential 
(>22 mV), higher entrapment efficiency (>80%) and amount of drug released at 20 h 
(80 to 90%), various CQAs were trade off. Demarcation of the optimized formulation 
was done by making the desirability function close to unity. The concentration of 
liquid lipid, Labrafil M2125 was kept as constant, i.e., 230 mg. Figure 9 portrays the 
optimum location of NLCs formulation within design space, construing the 
formulation composition with Compritol 888 (770 mg) and Tween 80 (365 mg), 
exhibiting the particle size of 215 nm, zeta potential of -26.3 mV, entrapment efficiency 
of 78% and Q16h of 83.6%, respectively. 
 
3.8 Caco-2 cell lines assays 
3.8.1 Cell viability assay 
As Caco-2 cells are very well to known possess similarity with the gastrointestinal 
epithelial cells, these are commonly used as the model cells for evaluating cytotoxicity, 
absorption and permeability of oral formulations (Kowapradit et al., 2010; Ma et al., 
2014). These cells undergo spontaneous enterocytic differentiation and become 
polarized, thereby expressing apical and basolateral surfaces exhibiting tight 
junctions, therefore used as bidirectional permeability model (Sambuy et al., 2005; 
Awortwe et al., 2014). Hence, in the current research work, this cell lines was employed 
as an in vitro model to evaluate drug absorption across intestine. Figure 10 (A) depicts 
the concentration-dependent percent cell viability at 24 h and Figure 10 (B) shows the 
time-dependent percent cell viability at 24 h, 36 h and 48 h  at highest concentration, 
i.e., 1000 µmol for Mgf, PL, physical mixture, PLCs and PLCs-NLCs. The percent cell 
viability data with Presto Blue on Caco-2 cells (Lea et al., 2014) was found to be >95% 
(p>0.05) for all the formulations, i.e., upto a maximum of 72 h, thus ratifying their 
safety and biocompatibility. Ideally, for better absorption and permeability, the 
formulation should not be toxic to the Caco-2 cells. Verily, Muller and associates have 
corroborated the safety of lipids on various cell lines in concentration of upto 10% 
(Müller et al., 1996; Müller et al., 2005). Indeed, none of the formulations, including 
Mgf, itself were found to be nontoxic to Caco-2 cells, and is  in consonance with the 
literature findings (Caliph et al., 2000). For improved understanding, the control cells 
at all the time points have been assumed as 100% and the cell viability for tested 
formulations has been calculated accordingly (Coker et al., 2012; Cheah et al., 2014). 
 
3.8.2 Bidirectional permeability assay 
Further, it was conferred vital to assess the permeability of the formed PLCs-NLCs 
across the intestinal epithelial barrier (Hubatsch et al., 2007). As Mgf is quite prone to 
P-gp efflux, the strategy aimed not only to study the A→B permeation but also to 
investigate the B→A transport. Mgf was analysed in both the A and B compartments 
to calculate the value of Papp (Figure 11). The TEER values were continuously 
recorded while performing experiment, showing miniscule reduction (i.e., <10%) in 
TEER value on the treated cells wrt the control cells which indicated that there was 
slight opening of the tight junctions of Caco-2 cells, signifying paracellular transport 
(Sha et al., 2005; Chen et al., 2015; Laksitorini et al., 2015). 
The prepared PLCs-NLCs and PLCs showed 10.1 fold (p <0.001) and 9.4 fold (p 
<0.001) enhancement, respectively in the permeation (19.2 × 10–6 cm/sec and 15.4 × 
10–6 cm/sec) parameters in contrast to the plain Mgf solution (1.9 × 10–6 cm/sec) at 3rd 
hour. This indicated that PLCs-NLCs demonstrated enhanced permeability of Mgf, 
solely attributable to the lipids and phospholipids employed to prepare the complex 
and NLCs (Gursoy et al., 2003; Gursoy and Benita, 2004; Kogan et al., 2008).  
The transport and permeability studies in Caco-2 monolayer determine the ability of 
a compound and/or formulation to act as a substrate and/or inhibitor of the efflux 
transporters of P-gp (Sun and Pang, 2008). Further, increase in the Papp with time 
might be due to the capacity of the excipients viz. phospholipids, lipids and 
surfactants to block the P-gp efflux mechanism across the intestinal barrier, resulting 
in more permeation over increasing time (Chaurasiya et al., 2012).  
3.8.3 Qualitative and quantitative cellular uptake 
 
Qualitative analysis made through the images were processed through  Zen Pro 2012, 
displayed the fluorescent images of Rh-123-loaded NLCs uptake at 1 h and 3 h points, 
with the corresponding histograms generated through Flowing software version 2.5.1 
(University of Turko, Finland) depict the quantitative data (Figure 12 A). Another set 
of images generated after fixation of cells exhibit DAPI stained nucleus of Caco-2 cells 
and Rh-123 loaded NLCs uptake at 1 h and 3 h (Fig 12B). Qualitative and quantitative 
analysis both made through the FITC value generated for respective time-points 
supported the time dependent uptake of 123 loaded NLCs upto 3h. This is in 
agreement with an earlier report where glyceryl monostearate lipid nanaoparticles 
showed maximum cellular uptake at 3 h  (Garanti et al., 2016). 
 
3.8.4  P-gp efflux assay 
The P-gp efflux assay revealed that at 37 °C, MDR1 and BCRP transporters were 
effluxing dyes, as the fluorescence intensity for both the dyes was observed to be quite 
low (Figure 13). On the other hand, incubation at 37 °C with vinblastine showed 
higher fluorescence indicating that vinblastine might block both the MRP2 and BCRP 
transporters (International, 2016). Meanwhile, incubating dyes-loaded PLCs 
(p<0.0001) and PLCs-NLCs (p<0.0001) with Caco-2 showed significantly higher 
fluorescence intensity than Mgf alone. Verily, significant difference around 2..1 folds 
was found between the fluorescence intensity of PLCs and PLCs-NLCs (p<0.001)  
which could be attributable to P-gp inhibition property of phospholipids and lipidic 
mixtures. These excipients primarily act as P-gp inhibitors by rendering P-gp 
substrate site competition (Roger et al., 2010; Hoosain et al., 2015).  In this context, 
Tween 80, being a surfactant also seemed to play significant role in inhibiting P-gp, 
leading to membrane fluidization and consequently, enhanced permeability (Rege et 
al., 2002). 
3.9 In situ intestinal perfusion studies 
The in situ SPIP study is a well-known model to investigate the absorption and 
permeation behaviour of a drug when administered as complex (Singh et al., 2009). As 
is evident from Figure 14, the PLCs showed significant improvement (P < 0.001) in he 
absorption number (An) by 12-fold (P < 0.001), fraction of drug absorbed (F) by 11-
fold (P <0.001), effective permeability (Peff) by 8-fold (P <0.001) and wall permeability 
(Pwall) by 12-fold (P <0.001) vis-à-vis free Mgf or co-administered with verapamil. 
Verapamil could bind with the P-gp efflux pumps present on the intestinal 
enterocytes, thereby allowing the Mgf to reach systemic circulation (Ishri et al., 2006). 
This study indisputably demonstrated the inherent P-gp efflux characteristics of Mgf, 
while the formed PLCs could surmount the P-gp efflux  (Madan et al., 2005). This can 
be attributed to the notable increase in the absorption potential of Mgf, due to 
enhanced permeability and absorption parameters by circumventing first-pass effect 
(Singh et al., 2011). Besides, the results unrevealed supremacy in permeability 
parameters by PLCs possibly due to phospholipids (Song et al., 2006; Zakeri-Milani et 
al., 2007). 
3.10 In vivo Pharmacokinetic Studies 
Statistically significant change in plasma concentration (p <0.001) was observed for 
PLCs-NLCs, PLCs than Mgf after peroral administration. The dose administered in 
each case, i.e., PLCs-NLCs, PLCs and Mgf, was equivalent to 30 mg/kg (Ma et al., 
2014). The mean plasma and time profiles for each group (n=6) is graphically depicted 
in Figure 15, depicting decline in the later part, thus, ratifying the suitability of 2-CBM 
kinetics (Bhattacharyya et al., 2013). The values of various pharmacokinetic 
parameters of PLCs and Mgf, and the results of post one-way Anova test are shown 
in Table 4. 
Nearly 4.55- and 1.98-fold increase in Cmax and AUC was recorded by PLCs-NLCs, 
while the corresponding PLCs demonstrated 3.61- and 1.78-fold augmentation vs Mgf, 
respectively. Moreover, the PLCs-NLCs and NLCs showed nearly 3-fold reduction in 
tmax values vs Mgf, therefore, suggested enhanced absorption with faster onset of 
action. Drastic increase for Ka, i.e., 5.14-fold, demonstrated increased oral absorption 
of PLCs-NLCs. Thus, significant different pharmacokinetic parameters confirm the 
better oral absorption of PLCs-NLCs over PLCs and Mgf.  
Together lipids, surfactants and absorption enhancers facilitate the increased 
bioavailability because of nanostructured NLCs, micellar solubilisation in intestinal 
milieu, followed by increased intestinal transport through transcellular and 
paracellular pathways (Porter et al., 2007).  
 
Table 4: Pharmacokinetic parameters obtained from plasma level studies after oral 
administration of PLCs-NLCs, PLCs and Mgf 
 
Treatment 
Formulations 
Pharmacokinetic parameters 
Cmax 
(ngh-1) 
AUClast  
h*ng/ml 
Cmax/AUC 
(h-1) 
Ka  
(h-1) 
Tmax 
(h) 
MRT 
(h) 
Cl 
(mL/h) 
Mgf 275.14 ± 
42.76 
2851.39 ± 
238.91 
0.096 1.08 ± 
2.1 
3.02 ± 
0.15 
9.72 ± 
1.27 
2331.64 
± 
591.71 
PLCs 1046.56 ± 
166.35 
5349.75 ± 
311.56 
0.196 0.35 ± 
0.12 
1.05 ± 
0.21 
12.72 ± 
1.87 
1445.51 
± 
265.12 
PLCs-NLCs 1319.12 ± 
178.53 
5948.72 ± 
378.26 
0.222 0.21 ± 
0.13 
1.03 ± 
0.36 
13.89 ± 
1.85 
1045.51 
± 
291.91 
All the data represented as mean ± SD (n=3) 
Although PLCs-NLCs did not show much significant improvement over the PLCs in 
the pharmacokinetic parameters (only 1.2 folds enhancement), yet the prepared PLCs-
NLCs exhibited quite superior results during inhibition of P-gp efflux activity (2.1 
folds), when conducted on Caco-2 cells. This can be ostensibly attributed to the 
presence of phospholipids and lipids present in the PLCs-NLCs, which act as P-gp 
substrates. Thus, the prepared PLCs-NLCs formulation primarily showed superiority 
on P-gp efflux inhibition potential, although not much significant effect on the 
pharmacokinetic profile. 
4. Conclusions:  
A dual formulation strategy was adopted in order to enhance the biopharmaceutical 
attributes of a very potent antioxidant, Mgf. A minimum stiochiometric ratio of 
Mgf:PL  (1:1) was observed to be good enough to form the complex on the basis of 
drug content, solubility and oil-water partition coefficient. Higher solubility and 
permeability values may lead to increased intestinal uptake and permeability, which 
is indeed a big limitation for oral absorption. Hence, the PLCs showed different 
morphological properties from Mgf and the physical mixture. Being semisolid in 
nature, attempts were made to incorporate Mgf in nanostructured carriers. Hence, a 
novel strategy with dual formulation, i.e., PLCs encapsulated in nanostructured 
systems was undertaken to improve the physicochemical and biopharmaceutical 
attributes of Mgf through in vitro, in situ and in vivo studies. The current research 
studies ratified that this drug–phospholipid complex loaded nanostructured dual 
system is a novel strategy to formulate BCS Class II and IV drugs. 
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Figures: 
 
 
 
 
 
Figure 1: Molecular docking images depicting binding of mangiferin with 
phosphatidylcholine transfer protein 
 
 
 
 
 
 
 
 
Figure 2:  X-ray diffraction patterns of (A) mangiferin; (B) Phospholipon 90 G; (C); 
physical mixture of mangiferin and Phospholipon 90 G (D) mangiferin-
Phospholipon 90 G complex 
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Figure 3: DSC thermograms of (A) mangiferin; (B) Phospholipon 90G; (C); physical 
mixture of mangiferin and Phospholipon 90G (D) Mangiferin-Phospholipon-90G 
complex (E) Complex loaded nanostructured lipidic systems 
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Figure 4: FTIR spectra of (A) mangiferin; (B) Phospholipon 90G; (C); Physical 
mixture of mangiferin and Phospholipon 90G (D) mangiferin Phospholipon 90G 
complex (E) Complex loaded nanostructured lipidic systems 
 
 
 
 
 
 
  
 
 
Figure 5: Scanning electron microscopic pictures of (A) mangiferin, (B) 
Phospholipon 90G, (C) Physical mixture of mangiferin and Phospholipon 90G (D) 
mangiferin–Phospholipon 90G complex 
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Figure 6: Morphological analysis of optimized PLCs-NLCs (A) particle size (B) TEM 
 
 
 
 
 
Figure 7: Mean percent drug release of mangiferin from various PLCs-NLCs 
formulations, prepared as per the experimental design. 
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Figure 8: 3D-Response surface plots showing the influence of ratio of solid: liquid 
lipids and Tween 80 on (A) Particle size (B) Zeta potential (C) Entrapment efficiency 
(D) Q16. 
 
 
 
Figure 9: Overlay plot depicting the design space region and optimized NLCs 
formulation of mangiferin (flagged). 
 
 
 
 
Figure 10:   Bar graphs depicting the Caco-2 cell viability scores with all the 
treatment formulations viz. Mgf: mangiferin; PL: Phospholipon 90G; PM: physical 
(A) (B) 
mixture of Mgf and PL; PLCs: Mangiferin:Phospholipon 90G mixture; PLCs-NLCs: 
PLCs-nanostructured lipidic systems at 24 h, 48 h, 72 h (Mean (n = 3) ± SD) 
 
 
 
 
Figure 11:  Bidirectional permeation study of various treatment of Mgf 
(mangiferin), PM (physical mixture), PLCs (mangiferin-Phospholipon 90G 
complex) and PLCs-NLCs (PLCs-nanostructured lipidic systems) on Caco-2 cells; 
value expressed in mean ±SD (n=3) 
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Figure 12: (A) Histograms and fluoescent images observed at 1h and 3 h for Rh-123 
loaded NLCs on Caco-2 cells (B) DAPI (Blue fluorscence) indicates the staining of 
nucleus while Rh-123 (green fluorscence) displays the uptake of NLCs at 1h and 3 
h. 
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Figure 13: Fluorescence index indicates the inhibition of the MDRI transporters for 
Rh-123-loaded formulations and BCRP transporters for DiOC2-loaded 
formulations. Each cross bar indicates ±SD (n = 3). 
 
 
 
 
 
Figure 14:  Increase in permeability and absorption paramaeters (in folds) of PLCs-
NLCs vis-a-vis Mgf, with and without verapamil across the rat intestine. Each cross 
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bar indicates + 1SD; Peff: effective permeability; Pwall: wall permeability; Fa: fraction 
of dose absorbed; An: absorption number 
 
 
 
 
 
Figure 15:  Mean plasma concentration-time curve of Mangiferin and 
Mangiferin-Phospholipon 90 G complex equivalent to 30 mg/mL (n=6), 
respectively; mean value of ± SD (LOQ obtained for the method in plasma is 36.55 
ng/mL). 
 
 
Supplementary Table 1: QTPP elements for NLCs of Mgf 
TPP Elements Target Justification 
Dosage form NLCs 
Selection of the nanostructured lipid-
based system helps in augmenting the 
oral bioavailability 
Dosage type 
Sustained 
release 
Slower and sustained release 
characteristics help in superior drug 
absorption potential 
Dosage strength 30 mg 
Unit dose of the drug recommended 
for the management of cancer 
Route of 
administration 
Oral 
Recommended route for delivery of 
Mgf to act as antioxidant 
Pharmacokinetics 
Higher Cmax and 
AUC, and 
extended tmax 
Required for achieving higher drug 
levels into the systemic circulation 
with enhanced therapeutic action for 
prolonged period of time  
Stability 
At least 24 
months at room 
temperature 
To maintain therapeutic potential of 
the drug during storage period 
 
 
Supplementary Table 2: CQAs for the NLCs of Mgf and justifications for them 
CQAs Target 
Is this  
a CQA? 
Justification(s) 
Particle size 
(nm) 
< 100 nm Yes 
Smaller globule size allows 
easy penetration of NLCs 
through gastrointestinal 
epithelial lining and 
paracellular pathways; hence 
was regarded as highly critical. 
Zeta potential 
(mV) 
> -15 mV Yes 
Optimum value of zeta 
potential in positive and/or 
negative sign is desired for 
maintaining stability of the 
system, thus considered as 
critical.   
Entrapment  
efficiency 
> 80% Yes 
Higher value of entrapment 
efficiency is desirable for 
attaining maximal therapeutic 
response. Hence, it was 
considered to be highly critical. 
Time required for  
80% drug release 
> 10-12 h Yes 
Sustained release characteristic 
is desired for attaining 
prolonged drug absorption, 
hence considered critical for 
the purpose.  
 
 
                      Supplementary Figure 1: Ishikawa fish bone diagram 
 
 
 
 
MPC-
loaded 
NLCs  
Measurements 
Personnel Material 
Methods Machines Environment 
Log P 
Solubility 
Size 
Charge 
Drug release 
Oil-water partition coefficient 
Drug conc. in blood 
Formulator 
QA Person 
QC Person 
Chemist 
Analyst 
Humidity 
Temperature 
Pressure 
Contamination 
Heat  
Lipid Type 
Surfactant Type 
Lipid Conc. 
Surfactant Conc. 
Distilled Water 
Drug Purity 
Hot  emulsification 
   Cytotoxicity and bidirectional  
permeability studies 
Entrapment Efficiency 
Characterization Studies 
Pharmacokinetic Studies 
UV-Vis Spectro 
Reflux condenser 
Magnetic Stirrer 
Particle Sizer 
HPLC Apparatus 
Disso 
Rota Evaporator 
Protein-drug interactions 
   In situ perfusion studies 
 Supplementary Table 3: Initial risk assessment for MPC-loaded NLCs 
CQAs 
RISK ESTIMATION MATRIX 
API  
particle 
size 
Type of 
phospholipid 
Type of 
surfactant 
Amount 
of solid 
lipid 
Amount 
of 
emulgent 
Reflux 
temperature 
and time 
Ultrasonication 
time and cycles 
 
Type of 
Stirring 
Stirring  
speed and 
time 
Homogeniser 
speed and 
time 
Assay Low Low Low Low Low Low Low Low Low Low 
Particle size 
(nm) 
Low Low Low High High Medium Medium Low Medium Medium 
Zeta potential 
(mV) 
Low Low Low High High Medium Medium Low Medium Medium 
Encapsulation 
efficiency 
(mg) 
Low Medium Low High High Medium Medium Low Medium Medium 
In vitro drug 
release (Q16) 
Low Low Low High High 
Low Low Low Low Low 
         High risk parameter          Medium risk parameter           Low risk parameter
56 
 
 
Supplementary Table 4:  Optimization studies enlisting the CMAs of NLCs for     
their respective low and high levels for employing FCCD 
Factors Type Levels 
Low (-1) High (+1) 
Solid lipid (X1) Numerical 700 mg 900 mg 
Tween 80 (X2) Numerical           250 mg 450 mg 
Optimization design as per thirteen factors, three level FCCD 
Trials                      Solid lipid Tween 80 
F1* 0 0 
F2* 0 0 
F3 0 1 
F4* 0 0 
F5 -1 1 
F6 0 -1 
F7* 0 0 
F8 1 1 
F9 -1 -1 
F10 1 0 
F11* 0 0 
F12 1 -1 
F13 -1 0 
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Supplementary Table 5: Linear regression data for calibration curve of mangiferin 
in human plasma (n=3) 
 
Parameters Values 
Linearity range (ng/band) 50–1000 
Regressed equation Y=3.038x + 1062 
Correlation coefficient 0.997± 0.0010 
Slope± SD 3.04 ± 0.557 
LOD 12.01 ng/mL 
LOQ 36.46 ng/mL 
 
 
